Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases

Publication date: February 2017
Source:Journal of the American Academy of Dermatology, Volume 76, Issue 2
Author(s): Mario Mandalà, Francesca Galli, Laura Cattaneo, Barbara Merelli, Eliana Rulli, Simone Ribero, Pietro Quaglino, Vincenzo De Giorgi, Jacopo Pigozzo, Vanna Chiarion Sileni, Alessandra Chirco, Pier Francesco Ferrucci, Marcella Occelli, Gianlorenzo Imberti, Dario Piazzalunga, Daniela Massi, Carlo Tondini, Paola Queirolo
BackgroundThe 7th edition of the TNM American Joint Committee on Cancer classification incorporates mitotic rate (MR) only for primary cutaneous melanoma (PCM) with Breslow thickness (BT) ≤1 mm.ObjectiveTo investigate whether and to what extent MR is able to predict sentinel lymph node (SLN) status and clinical outcome of PCM patients with BT >1 mm.MethodsThe study included consecutive patients with PCM. Logistic regression and Cox regression model were used to analyze the impact of MR on SLN status, disease-free survival (DFS), and overall survival.ResultsFrom 1998 to 2015, 1524 PCM (median age 57.8 years) cases were diagnosed with a BT >1 mm in six centers of the Italian Melanoma Intergroup. Median follow-up was 5.0 years. By multivariate analysis, MR was associated with SLN positivity (odds ratio 1.98, 95% confidence interval [CI] 1.12-3.50, P = .018). After adjusting for BT, ulceration, age, sex, and SLN status, MR correlated with a poor DFS (hazard ratio 1.52, 95% CI 1.18-1.97, P = .002) and overall survival (hazard ratio 1.63, 95% CI 1.17-2.29, P = .004).LimitationsRetrospective analysis.ConclusionMR is an independent prognostic factor for PCM patients with BT >1 mm. Incorporating this tissue biomarker could provide a better stratification of patients entering clinical trials in the adjuvant setting.



http://ift.tt/2j7ZYoX